I graduated with a PhD in chemistry from the University of Heidelberg, Germany in 1995. I spent a year as a Postdoc at Cornell University in Ithaca, NY, then worked as a medicinal chemist for GlaxoSmithKline in Cape Town, South Africa.
I joined Austin Health in 1998 as a radiochemist. Initially, I did a lot of carbon-11 work and established the procedure for the first C-11 PIB scan in Australia. I have extensive experience in performing first-in-human studies with neuroscience and oncology tracers labelled with C-11, F-18 and Zr-89. My main research interests are in synthesis automation, labelling of peptides ad antibodies as well as hypoxia.
Reported by 9News, Clinical Director of The Florey Professor Graeme Jackson was interviewed about the technology developed at the Australian Epilepsy project.
26 June 2025
Donanemab, developed by Lilly, is the first disease-modifying treatment for early-stage Alzheimer’s disease to be approved for use in Australia. The National Imaging Facility supported its developme
16 June 2025
Dr Sicong Tu is excited about helping motor neurone disease (MND) patients gain a much better idea of their disease progression: “The focus of our network is on bridging the gap between leading Aust
28 May 2025
A new national-scale molecular-imaging network that aims to improve cancer imaging, dementia diagnosis and treatment, and new radiopharmaceuticals was launched Saturday at the annual meeting for Austr
26 May 2025
Rebecca V Robertson, Noemi Meylakh, Lewis S Crawford, Fernando A Tinoco Mendoza, Paul M Macey, Vaughan G Macefield, Kevin A Keay, Luke A Henderson
Read Publication
Joseph J. Bartlett, Catherine E. Davey, Leigh A. Johnston, Jinming Duan
Read Publication